YES Inhibitors
3 drugsAbout YES
YES (YES1), a non-receptor tyrosine kinase, functions in cellular signaling pathways. It plays a role in cell growth, differentiation, and survival, making it a compelling target in oncology.
YES is genetically linked to 16 diseases including hypertension (score 0.76) and skeletal abnormalities (score 0.68), providing strong support for therapeutic intervention. Strong eQTL/pQTL signals further support its role in disease.
Three FDA-approved small molecule drugs, including SPRYCEL, DASATINIB, and PHYRAGO, target YES for oncology indications. These drugs demonstrate YES's druggability and clinical relevance.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Advanced Lymphoma with only 2 trials.
- phase1 represents biological uncertainty with 55% completion.
Human Genetic Evidence Strong
YES has strong genetic support with a max score of 0.76 linked to hypertension.
The strong genetic support suggests a higher likelihood of clinical success for YES-targeting therapies.
Evidence Across Diseases
16 totalGWAS and other genetic studies link YES1 to 16 diseases.
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for YES1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Apotex, HANDA THERAP, and Bristol-Myers Squibb are the companies with approved drugs targeting YES.
The presence of only 3 companies suggests a relatively unconcentrated market with potential entry opportunities.
Drug Modality Landscape
Modalities
Routes of Administration
YES is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
Clinical Trials 253 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 104 | 58 | 32 | 14 | 64% |
| Phase 2 | 125 | 54 | 29 | 40 | 65% |
| Phase 3 | 16 | 9 | 2 | 5 | 82% |
| Phase 4 | 8 | 3 | 1 | 4 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2006 - 2023)
The first drug targeting YES was approved in 2006, with the most recent approval in 2023.
The 18-year span indicates sustained interest, but recent approval suggests renewed opportunities for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 121 clinical trials targeting YES.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities